Cysteinyl-leukotriene1 receptor antagonist prevents urological cancer cell growth through early apoptosis.

Recent studies have demonstrated that the cysteinyl-leukotriene1 receptor (CysLT1R) antagonist induces the growth arrest of cancer cells through apoptosis. In this study, we examined the effects of the CysLT1R antagonist on cell proliferation in urological cancer cell lines, including renal cell carcinoma, bladder cancer, prostate cancer and testicular cancer cells. The inhibitory effect of the CysLT1R antagonist on the urological cancer cells was investigated using the MTT assay and flow cytometry. The CysLT1R antagonist induced a reduction in cell viability with a half-maximal concentration of growth inhibition in all the urological cancer cell lines, and arrested the growth of the cells through early apoptosis. In conclusion, the CysLT1R antagonist may mediate potent anti-proliferative effects against urological cancer cells through early apoptosis, and may therefore serve as a novel therapeutic target in the treatment of urological cancer.